抗肿瘤药紫杉醇的不良反应及临床合理用药评价

Evaluation of Adverse Reactions and Clinical Rational Use of Anti-tumor Paclitaxel

目的研究抗肿瘤药紫杉醇的不良反应及临床合理用药情况。方法回顾性分析2017年1月至2018年12月接收50例肿瘤患者临床资料,50例患者均实施紫杉醇单一用药或与其他药物联合治疗,监测其治疗后不良反应发生率,分析合理用药价值。结果 50例实施紫杉醇治疗者47(94.00%)例出现骨髓抑制、44(88.00%)例出现脱发、32(64.00%)例出现胃肠道反应、27(54.00%)例出现手足麻木、18(36.00%)例出现水肿、16(32.00%)例出现肝脏毒性、15(30.00%)例出现神经毒性、7(14.00%)例过敏反应、5(10.00%)例关节及肌肉痛、5(10.00%)例血液系统、3(6.00%)例肾脏毒性、2(4.00%)例心脏毒性、2(4.00%)例发热等不良反应。结论紫杉醇为常见抗肿瘤药物,但其安全性不高,因此治疗中需谨慎用药严格控制给药时间,治疗前还需做好预防性措施,以降低紫杉醇治疗不良反应发生率。

Objective To study adverse reactions and clinical rational use of paclitaxel.Methods Review and analyzed clinical data of 50 cases cancer patients treated in our hospital from January 2017 to December 2018.All cases were treated with paclitaxel only or in combination with other drugs.Monitor incidence of adverse reactions after treatment and analyze value of rational drug use.Results Among 50 cases treated with paclitaxel,47 (94.00%) had myelosuppression,44 (88.00%) had alopecia,32 (64.00%) had gastrointestinal reaction,27 (54.00%) had hand and foot numbness,18 (36.00%) had edema,16 (32.00%) had liver toxicity,15 (30.00%) had neurotoxicity,7 (14.00%) had allergic reaction,and 5 (10.00%) had joint And muscle pain,5 (10.00%) cases of blood system,3 (6.00%) cases of renal toxicity,2 (4.00%) cases of cardiac toxicity,2 (4.00%) cases of fever and other adverse reactions.Conclusion Paclitaxel is common anti-tumor drug,but its safety is not high.Therefore,it is necessary to use drugs carefully,control administration time strictly,and take preventive measures before treatment to reduce its incidence of adverse reactions.